Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 5, 2006, Pages 806-809

  Barreiro, Pablo ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

CD4+; Purine nucleoside phosphorylase; Purines; T lymphocytes

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NUCLEOSIDE ANALOG; PURINE NUCLEOSIDE PHOSPHORYLASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ANTIVIRAL ACTIVITY; BODY WEIGHT DISORDER; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG ACTIVATION; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; EDITORIAL; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; IMMUNE RESPONSE; LIPOATROPHY; LYMPHOCYTOPENIA; MITOCHONDRIAL TOXICITY; NONHUMAN; PANCREATITIS; T CELL DEPLETION; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; WEIGHT REDUCTION;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DIDANOSINE; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; MITOCHONDRIA; PHOSPHONIC ACIDS; PURINE-NUCLEOSIDE PHOSPHORYLASE;

EID: 33645803189     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl045     Document Type: Editorial

References (16)

1. Kearney B, Flaherty J, Shah J. Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43: 595-612.
2. Pecora P, Kirian M. Effect of TDF on ddl absorption in patients with HIV. Ann Pharmacother 2003; 37: 1325-8.
3. Ray A, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004; 48: 1089-95.
4. Pruvost A, Negredo E, Benech H et al. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in HIV-infected patients. Antimicrob Agents Chemother 2005; 49: 1907-14.
5. Martinez E, Milinkovic A, de Lazzari E et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 2004; 364: 65-7.
6. Palacios R, Santos J, González M et al. Reduction in body weight and CD4 lymphocyte count with simplification regimens including TDF and ddl. A scheme to avoid? In: Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, 2004. Abstract P19.
7. García-Benayas T, Barrios A, Sánchez-Conde M et al. Higher risk of hyperglycemia in patients under didanosine and tenofovir-containing regimens. In: Twelfth Conference on Retroviruses and Opportunistic Infections. Boston, 2005. Abstract 829.
8. Robbins B, Wilcox C, Fidland A et al. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 2003; 23: 695-701.
9. Brinkman K, ter Hofstede HJ, Burger DM et al. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44.
10. Negredo E, Molto J, Burger D et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18: 459-63.
11. Barrios A, Rendón A, Negredo E et al. Paradoxical CD4+ T cell decline in HIV-infected patients with complete virus suppression under tenofovir plus didanosine combinations. AIDS 2005; 19: 569-75.
12. Arpaia E, Benveniste P, Di Cristofano A et al. Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med 2000; 191: 2197-207.
13. Markert ML. Purine nucleoside phosphorylase deficiency. Immunodefic Rev 1991; 3: 45-81.
14. Jemsek J, Hutcherson P, Harper E. Poor virological responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir DF. In: Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, 2003. Abstract 51.
15. Maitland D, Moyle G, Hand J et al. Early virological failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005; 19: 1183-8.
16. Podzamczer D, Ferrer E, Gatell J et al. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther 2005; 10: 171-7.